Joint Global Coordinator and Joint Bookrunner
Kempen & Co acted as Joint Global Coordinator and Joint Bookrunner in MaaT Pharma’s €31.5 million Initial Public Offering
MaaT Pharma is a clinical-stage company with a well-established approach to restoring patient-microbiome symbiosis to improve survival outcomes in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients and completed a Phase II clinical trial. Their discovery and analysis platform, gutPrint®, supports the development and expansion of the company’s pipeline by determining novel disease targets, evaluating drug candidates and identifying biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to establish the utilization of microbiome treatment integration into clinical practice. The company is headquartered in Lyon, France.
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: